Beximco Pharmaceuticals Ltd Payment of Cash Dividend
31 January 2025 - 1:59AM
RNS Regulatory News
RNS Number : 3393V
Beximco Pharmaceuticals Ltd
30 January 2025
30 January 2025
BEXIMCO PHARMACEUTICALS LIMITED
Payment of Cash Dividend
Beximco Pharmaceuticals Limited ("Beximco Pharma",
"BPL" or "the Company"; AIM Symbol: BXP, LEI No.:
213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic
pharmaceutical products and active pharmaceutical ingredients,
today announces that the 40% cash dividend of the nominal value per
ordinary share/GDR (Taka 4.00 per ordinary share/GDR) for the year
ended 30 June 2024, which was approved in the Annual General
Meeting ("AGM") held on 29 December 2024, has been deposited with
the custodian bank (HSBC) in Dhaka on 26 January 2025 and
subsequently credited to the Depository.
For any queries regarding the credit of dividend to
respective accounts of holders of GDRs, please contact the
Depository (The Bank of New York Mellon) representative, Mr. Vinu
Kurian, at vinu.kurian@bnymellon.com.
For further
information please visit www.beximcopharma.com or enquire
to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.
20111
Mohammad Ali Nawaz, Chief Financial
Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited
(Nominated
Adviser)
Mark Brady / Andrew
Emmott
Tel: +44 (0)20 3368 3551 /
3555
SP Angel Corporate Finance LLP
(Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI
Consulting
Simon Conway / Victoria Foster Mitchell / Sam
Purewal
Tel: +44 (0)20 3727
1000
Notes to
Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter
of medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical
companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 6,000
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the region.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DIVEALFEDSNSEFA
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Jan 2025 to Feb 2025
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Feb 2024 to Feb 2025